[Preventive effect of trans-resveratrol on hypertension-induced cardiac hypertrophy in partially nephrectomized rats].
OBJECTIVE
To investigate the effect of trans-resveratrol on hypertension-induced cardiac hypertrophy and its potential mechanisms involving endothelin (ET), angiotensin II (AngII) and nitric oxide (NO).


METHODS
Animal models bearing cardiac hypertrophy were replicated in male SD rats following partially nephrectomy (PNX). 10 mg/kg bw or 50 mg/kg bw of resveratrol was administered to rats by gavage, respectively, for 4 weeks. PNX control and sham-operation control (SHAM) were simultaneously established. Systolic pressure of rats was measured through tail at baseline and it, as well as heart weight, was measured after 4-week treatment. Serum ET-1 and AngII concentrations were determined using radioimmunological assay and NO using nitric acid reductase method.


RESULTS
After 4-week treatment, animals in PNX control group had significantly higher systolic pressure and heart weight, higher ET-1 and AngII concentrations while lower NO concentrations, compared with those in SHAM group (P < 0.05). Rats treated with 50 mg/kg bw of resveratrol had significantly lower systolic pressure and heart weight, lower ET-1 concentrations while higher NO concentrations, compared with animals in PNX group (P < 0.05).


CONCLUSIONS
Trans-resveratrol could protect against the increase of systonic pressure and subsequent cardiac hypertrophy in vivo, which mechanisms might, at least partly, involve with its modulation on NO, AngII and ET.
Liu
Zhao-ping
ZP
Institute of Nutrition and Food Safety, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Song
Yan
Y
Liu
Ze-qing
ZQ
Zhang
Xiao-peng
XP
D000804:Angiotensin II / Q000097:blood; D000818:Animals; D006332:Cardiomegaly / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood; D006973:Hypertension / Q000150:complications*; D008297:Male; D009206:Myocardium / Q000473:pathology; D009392:Nephrectomy; D009569:Nitric Oxide / Q000097:blood; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
D002317:Cardiovascular Agents; D019332:Endothelin-1; D013267:Stilbenes; D000804:Angiotensin II; D009569:Nitric Oxide; D000077185:Resveratrol